Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Crispr Therapeutics

Evaluate

Thumbnail
July 17, 2023

Sanofi goes back to Scribe

The latest deal focuses on in vivo Crispr editing for sickle cell disease, and follows last year’s cancer collaboration.

Thumbnail
June 26, 2023

ADA 2023 – Vertex raises hopes of type 1 diabetes cure

But it still has a long way to go with its islet cell therapies.

Article image
Vantage logo
June 15, 2023

Lilly signs up Verve to take on Novartis and Amgen

Today’s $60m deal is focused on Lp(a), a new cardiovascular target for the gene editing company.

Article image
Vantage logo
June 12, 2023

EHA 2023 – Editas hopes to be better, although late

Article image
Vantage logo
June 09, 2023

EHA 2023 – Crispr sets a date with the US regulator

Article image
Vantage logo
May 19, 2023

Scribe signs another big pharma deal

Lilly is the latest group, after Biogen and Sanofi, to collaborate on Scribe’s novel approach to Crispr editing.

Article image
Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Alzheimer’s has already grabbed attention but plenty of big regulatory decisions still loom for Sarepta, Crispr, Astellas and more.

Article image
Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

A new report from Evaluate Vantage looks at recent developments in gene editing and delivery.

Article image
Vantage logo
March 27, 2023

Another diabetes cell therapy deal for Vertex

Article image
Vantage logo
March 24, 2023

Spotlight – Vertex flexes its dealmaking muscle

The developer has two new collaborations in rare dystrophies, with Entrada and Tevard, but work is early and certain rivals are some way ahead.

Article image
Vantage logo
March 07, 2023

Merck leads the new cholesterol-lowering push

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up